Previous Treamted
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC (NCT07562581) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-06-01 |
Track Previous Treamted automatically
Every clearance here is in the API, with alerts when new ones post.